SCHEMBL20114914

SCHEMBL20114914

CSC(C)(C)c1ccccc1-c1nccs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.43
P2RX7 Q99572 1/20 0.38
ADRA1A P35348 2/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1B P35368 1/20 0.36
RAB9A P51151 1/20 0.36
ADORA2A P29274 2/20 0.36
ADORA1 P30542 2/20 0.36
ADRA2A P08913 1/20 0.36
CYP2A6 P11509 1/20 0.36
EDNRB P24530 1/20 0.36
EDNRA P25101 1/20 0.36
MAT2A P31153 1/20 0.35
PLA2G7 Q13093 2/20 0.35
ALDH1A1 P00352 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP17A1 P05093 1/20 0.34
S1PR1 P21453 1/20 0.34
ADRB2 P07550 1/20 0.33
TUBB4A P04350 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17030749 0.83 PDPK1 (0.48) PDPK1P2RX7ADRA1AADRA1DADRA1B
SCHEMBL19695750 0.81 PDPK1 (0.46) PDPK1P2RX7ADRA1AADRA1DADRA1B
SCHEMBL27763733 0.78 PDPK1 (0.43) PDPK1P2RX7ADRA1AADRA1DADRA1B
SCHEMBL3058083 0.77 ALDH1A1 (0.51) PDPK1P2RX7RAB9AALDH1A1TDP1
SCHEMBL17194980 0.76 ADORA2A (0.42) PDPK1P2RX7ADRA1AADRA1DADRA1B
SCHEMBL5692672 0.75 PDPK1 (0.64) PDPK1ADRA1AADRA1DADRA1BRAB9A
SCHEMBL1047236 0.74 PDPK1 (0.53) PDPK1ADRA1AADRA1DADRA1BRAB9A
SCHEMBL5014843 0.73 PDPK1 (0.48) PDPK1ADRA1AADRA1DADRA1BRAB9A
SCHEMBL1951149 0.73 PDPK1 (0.61) PDPK1ADRA1AADRA1DADRA1BRAB9A
SCHEMBL996777 0.71 PDPK1 (0.53) PDPK1ADRA1AADRA1DADRA1BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370386-B2 Substituted quinolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2019-08-06 US disclosed
US-20180118757-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118757-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS PDPK1 891/4885P2RX7 3188/4885ADRA1A 568/4885
US-10370386-B2 Substituted quinolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS PDPK1 1588/4885P2RX7 2908/4885ADRA1A 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.